Related by context. All words. (Click for frequent words.) 89 Reports Positive 81 Receives Positive 81 Presents Positive 80 Announces Initiation 79 Completes Enrollment 79 Announces Preliminary 79 Announces Successful Completion 78 Announces Commencement 78 Reveals Positive 78 Updates Status 77 Receives Milestone Payment 77 Announces Successful 77 Completes Patient Enrollment 77 Announces Termination 76 Receives Approval 76 Provides Update Regarding 76 Announces Presentation 76 Provides Update 76 Announces Completion 76 Receives Notice 76 Receives Orphan Drug Designation 75 Initiates Phase 75 Announces Receipt 75 Announces Publication 75 Presents Preclinical Data 75 Updates Shareholders 75 Successfully Completes 75 Completes Initial 75 Initiates Phase II 75 Commences Phase 75 Jointly Announce 75 Receives Conditional Approval 75 Announces Filing 74 Positive Results 74 Exercises Option 74 Receives Favorable 74 Provides Operational Update 74 Receives FDA Clearance 74 Completes Financing 74 Provides Updates 74 Enrolls First 74 Receives Patent 74 Closes Acquisition 74 Announces Issuance 74 Receives Regulatory 74 Announce Completion 74 Attains 73 Announces Signing 73 Announces Closing 73 Closes Private Placement 73 Shows Promise 73 Announces Non Brokered 73 Announces Acquisition 73 Provides Preliminary 73 Drug Candidate 73 FDA Clears 73 Receives Notification 73 Completes Private Placement 73 Receives Conditional 73 Announces Private Placement 73 Announce Receipt 73 Initiates Clinical Trial 72 Commences Drilling 72 Net Loss Widens 72 Announces Favorable 72 Announces Revised 72 Announces Resignation 72 Announces FDA Clearance 72 Demonstrates Positive 72 Announce License Agreement 72 Closes Second Tranche 72 Presents Positive Preclinical 72 Begins Dosing 72 Obtains 72 Q4 Loss Widens 72 Consummates 72 Q3 Loss Widens 72 Enters Into Agreement 72 Secures Financing 72 Finalizes Acquisition 72 Significantly Improves 72 Begins Drilling 72 Releases Third Quarter 72 Phase 2b Clinical Trial 72 Receives Approvable Letter 72 Reacquires 72 Acquires Exclusive 72 Announces Appointment 72 Drilling Underway 72 Initiates Phase III 72 Announces Proposed 72 Provides Clarification 72 Finalizes Agreement 72 Signs Option Agreement 72 Completes Successful 72 Q4 Loss Narrows 72 Initiates Clinical Trials 71 Announce Merger Agreement 71 Reports Receipt 71 Adopts Shareholder Rights 71 Enters Into 71 Files IND 71 Enters Agreement 71 Presents Preclinical 71 Q3 Loss Narrows 71 IIROC Resume 71 Announces Stock Repurchase 71 Completes Drilling 71 Completes Purchase 71 Initiates Clinical 71 Present Preclinical Data 71 Subsidiary Enters 71 Initiates Enrollment 71 Collaborators Present 71 Shareholders Approve Acquisition 71 Significantly Increases 71 Q2 Loss Widens 71 Submits Application 71 Jumps Higher 71 Confirms Receipt 71 Announces Shareholder Approval 71 Sinks Lower 71 Completes Merger 71 Licenses Novel 71 Announces Additions 71 Closes Financing 71 Closes Sale 71 Acquires Assets 71 Submits Biologics License Application 71 IIROC Halt 71 Achieves Positive 71 Signs Licensing Agreement 71 Shareholders Approve Merger 71 Announces Formation 71 Completes Acquisition 71 Announces Addition 71 Obtains Approval 71 Announces 71 Increases Ownership 70 Releases Second Quarter 70 Initiates Dosing 70 Clinical Trial Results 70 Announces Licensing Agreement 70 FDA Approves 70 Submits NDA 70 Results Confirm 70 Q2 Loss Narrows 70 Shareholders Approve 70 Files Shelf Registration Statement 70 Announces Effective Date 70 Net Loss Narrows 70 Demonstrates Significant 70 Cites Positive 70 Significantly Reduces 70 Reconfirms 70 Sign License Agreement 70 Significantly Expands 70 Announces Departure 70 Closes Previously Announced 70 Subsidiary Signs 70 Achieves Milestone 70 Reports Profitable 70 Receives Orphan Drug 70 Sign Licensing Agreement 70 More Than Doubles 70 Resumes Drilling 70 Announces Availability 70 Provides Guidance 70 Shows Promising 70 Meets Primary Endpoint 70 Discontinues 70 Commences 70 Finalizes Purchase 70 Executes Agreement 69 Significant Increase 69 Announces Postponement 69 Awarded Patent 69 Announces Cancellation 69 Reports Third Quarter 69 Announces Normal Course 69 Successfully Closes 69 Phase IIb Trial 69 Reports Second Quarter 69 Announces Release Date 69 Shareholder Opinions 69 Completes 69 Secures Additional 69 Announces Expiration 69 Completes Merger With 69 Secures Funding 69 BayStreet.ca Research Alert 69 Enter Into 69 Increases Size 69 Confirms Significant 69 Therapeutic Competitors Companies 69 Acquires Controlling Interest 69 Amends Agreement 69 CRWESelect CRWESelect.com Highlights 69 Announces Second Quarter 69 Commence Drilling 69 Receives Complete Response 69 Successfully Completed 69 Regains Compliance With 69 Signs Agreements 69 Study Evaluating 69 Closes Acquisition Of 69 Q1 Loss Narrows 69 Subsidiary Acquires 69 Announces Divestiture 69 Updates Guidance 69 Completes Patient Enrolment 69 Progresses 69 Finalizes 69 Grants Options 69 Announces Expanded 69 Announces Proposed Acquisition 69 Q1 Loss Widens 69 Announce Commencement 69 Completes Sale 69 Announces Dismissal 69 Announces License Agreement 69 Amends Terms 69 Receives Fast Track 69 Receives Commitment 69 FDA Accepts 69 Seeks Approval 69 Announces Launch 69 Announce Initiation 69 Renegotiates 69 Settles Litigation 68 Reports Fiscal 68 Posts Higher 68 Commence Phase 68 Trial Evaluating 68 Announces Intention 68 Identifies Potential 68 Preclinical Data 68 Announce Signing 68 Completes Acquisitions 68 Subsidiary Receives 68 Changes Name 68 Successfully Completes Phase 68 Submits 68 Commences Exploration 68 Posts Wider Loss 68 Reminds Shareholders 68 Study Demonstrates 68 Gets Approval 68 Extends Tender Offer 68 Announce Settlement 68 Signs License Agreement 68 Achieves Significant 68 Regains Compliance 68 Patient Enrollment 68 Receives NASDAQ 68 Enters Into Letter 68 Reports Significantly Improved 68 Receives Favorable Ruling 68 Joins OTCQX 68 Announces Granting 68 Initiates 68 Receives Positive Results 68 Receives Order 68 Receives Unsolicited 68 Pinnacle Digest Looking 68 Announce Licensing Agreement 68 Files Registration Statement 68 Strengthens Balance Sheet 68 Signs Definitive Agreement 68 Discloses 68 Announce Collaboration Agreement 68 Completes Transaction 68 Starts Drilling 68 Completes Previously Announced 68 Acquire Assets 68 Drilling Commences 68 Drilling Intersects 68 Q2 Profit Declines 68 Board Unanimously Rejects 68 Announces Adjournment 68 FDA Okays 68 Provides Shareholder 68 Earns Milestone Payment 68 Increases Stake 68 Appoints 68 Successful Completion 68 Flamel Technologies Announces 68 Secures 68 Achieves Primary Endpoint 68 Has Received 68 Phase III Clinical Trial 68 Rated Speculative Buy 68 Receives 68 Sets Date 68 Q2 Profit Rises 68 Submits Supplemental 68 Announces Stockholder Approval 67 Successfully Complete 67 Terminates Contract 67 FY# Loss Widens 67 Announces Assay Results 67 Swings To 67 Declares Increased 67 Files Patent Application 67 Announces Early Termination 67 Commences Trading 67 Issues Guidance 67 Announces Fiscal 67 Zacks Analyst Blog Highlights 67 www.otc advisors.com names 67 Announces Expansion 67 Phase IIb Clinical Trial 67 Canada Trade Resumption 67 Explore Strategic Alternatives 67 Sign Definitive Agreement 67 Announces Third Quarter 67 Monetizes 67 Board Authorizes 67 Issues Statement Regarding 67 Extends Offer 67 Declares Increase 67 Recommences 67 Announces Upcoming 67 Obtains FDA 67 Shares Surge 67 Receives Positive Opinion 67 Annouces 67 Announces Bought Deal 67 Announce Agreement 67 Stockholders Approve 67 Files Preliminary Prospectus 67 CORRECTION FROM SOURCE 67 Announces Definitive Agreement 67 Strengthens Its 67 Stockholders Approve Merger 67 Signs Letter 67 Wins Approval 67 Drilling Completed 67 Announces Cash Dividend 67 Aquires 67 Acquirer Company 67 Signs Agreement 67 Q3 Profit Rises 67 Q4 Profit Declines 67 Announce Collaboration 67 Enters Into Strategic 67 Oral Calcitonin 67 Receives Permit 67 Receives Tentative Approval 67 Announces Share Repurchase 67 Further Strengthens 67 Regains Full 67 Q4 Profit Rises 67 Smartstox.com Spotlights 67 Nears Completion 67 Drug Fails 67 Enters Into Definitive Agreement 67 Initiate Phase III 67 Provides Updated 67 Completes Second Tranche 67 Signs LOI 67 Announces Retirement 67 Announces Immediate Availability 67 Enters Into License Agreement 67 Commences Operations 67 PPD Declares 67 Reports Assay Results 67 Canada Trading Halt 67 Spins Out 67 Announces Debt Settlement 67 Announces Operational Update 67 Acquires 67 Previously Announced 67 Complete Merger 67 Regains 67 Expands Scientific Advisory 67 Clarifies Status 67 Introduces Revolutionary 67 Retains Investor Relations 67 Receives Confirmation 67 Q3 Profit Declines 67 Announces Underwriters Exercise 67 TSX Delisting Review 67 Re Affirms 67 Granted Orphan Drug 67 Enters Into Joint Venture 66 Reduces Risk 66 Initiates Drilling 66 Phase IIa Clinical Trial 66 Phase III Trial 66 Downtrend Spotted 66 Obtains License 66 Proudly Announces 66 Phase 2a Trial 66 Completes Installation 66 Approve Merger 66 Q1 Profit Rises 66 Univest Corporation Declares 66 Announces Enhancements 66 Announces Dividend 66 Introduces Next Generation 66 Posts Record 66 Commences Drill Program 66 Announces Participation 66 Commercialize 66 Record Third Quarter 66 Posts Strong 66 Study Confirms 66 Shares Soar 66 Achieves Record 66 Novel Oral 66 Gets FDA Clearance 66 Receives Approval From 66 Reports Record 66 Reports Preclinical Data 66 Drilling Extends 66 Announces Poster Presentations 66 Announces Tentative Approval 66 Completes Tender Offer 66 Confirms 66 Pivotal Phase III 66 Lupus Drug 66 please visit http:/www.stockguru.com 66 Completes Sale Of 66 Conference Call TRANSCRIPT 66 Unveils Latest 66 Announces Refinancing 66 Successfully Tests 66 L.P. Announces 66 Summarizes 66 Announces Quarterly 66 Improves Survival 66 Resubmits 66 Engages 66 Acquire Controlling Interest 66 Closes Non Brokered 66 Reaches Agreement 66 Private Placement Closed 66 Maintains Strong 66 Completes Conversion 66 -gamma secretase modulator 66 Files Revised 66 Taglich Brothers Initiates Coverage 66 Files NI #-# 66 Expects Higher 66 Develop Novel 66 Q1 Profit Declines 66 Announce Expiration 66 Outperforms 66 Completes Expansion 66 Directors Authorizes 66 Extends Maturity 66 CybeRelease Decliners 66 Expand Collaboration 66 Terminates 66 Announce Early Termination 66 Completes Reverse Merger 66 Files Amended 66 Commences Tender Offer 66 AllPennyStocks.com Spotlights 66 Nine Month 66 Settle Patent Litigation 66 Receives Shareholder Approval 66 Commences Production 66 Successfully Completes Tender Offer 66 Completes Purchase Of 66 BioSante Pharmaceuticals Announces 66 Launches Enhanced 66 Completes Due Diligence 66 Uptrend Spotted 66 Restructures 66 Announcement Regarding 66 Amends Private Placement 66 Phase 2b Trial 66 Announce Successful Completion 66 Launches Next Generation 66 Immunomedics Announces 66 Mobilizes 66 Announces Resumption 66 Receives Clearance 66 Welcomes Analyst Initiation 66 TriCo Bancshares Announces 66 Winning Streak Continues 66 Investigational Compound 66 Q3 Profit Surges 66 Restate Financial 66 Announce Definitive Agreement 66 Announces Record Date 66 VIVUS Announces 66 Announces Organizational Changes 66 Signs Lease 66 Receives Certification 66 Announces Discontinuation 66 Schedules Second Quarter 66 Signs MOU 66 Commences Drilling Program 66 Commences Phase III 66 Receives Prestigious 65 Signs Definitive 65 Dramatically Increases 65 Demonstrates Long Term 65 Extends Expiration Date 65 Formalizes 65 Ink Deal 65 Terminates Agreement 65 Appoints Seasoned 65 Completes Dosing 65 Inks Pact 65 Receives SFDA Approval 65 Delays Filing 65 Initiates Phase 2b 65 Identifies Significant 65 Validates 65 Increases Private Placement 65 Patent Covering 65 Awarded Qualifying Therapeutic 65 Announce Second Quarter 65 Furthers 65 Completes Divestiture 65 Review Initiated 65 Submits IND 65 Inc. Nasdaq OXGN 65 Announces Redemption 65 Mutually Agree 65 Options Trader Alert 65 Achieves Record Sales 65 PRN FDA Approves 65 Study Showed 65 Earnings Rise 65 Closes Merger 65 Crowflight Announces 65 Releases Next Generation 65 Successfully Concludes 65 Evaluate Strategic Alternatives 65 Announces Dates 65 Announce Merger 65 Sells Shares 65 Skymark Research Initiates Independent 65 Arranges Private Placement 65 Dutton Associates Announces 65 Releases Latest 65 Amends Credit 65 Single Dose 65 Quadruples 65 Q4 Profit Surges 65 Reports Fourth Quarter 65 Demonstrates Potential 65 Moves Forward 65 Guides Below 65 Enters Into Merger Agreement 65 CRWEWallstreet.com Stock Report 65 Spectrum Pharmaceuticals Announces 65 Novartis Novo Nordisk 65 Report Initiates Independent 65 Attracting Bullish Investors 65 Receives CE 65 Host Third Quarter 65 Commence Trading 65 Plummets 65 Study Indicates 65 Announces Intent 65 Announces Pricing 65 Voluntarily Withdraw 65 TSX Delisting 65 Mobilizes Drill 65 Sees Positive 65 Enters Into Agreements 65 Launches Innovative 65 Drill Results 65 Declares Dividend 65 Satisfies 65 Signs Long Term 65 Submits Response 65 Irw Press 65 Stays Neutral 65 Jointly Develop 65 Elevates 65 OTCStockExchange.com Stock Alert 65 Restates 65 Secures Long Term 65 Has Commenced 65 &Amp; 65 Record Second Quarter 65 Initiates Coverage 65 Completes Integration 65 Ranked Number 65 Posts Quarterly 65 Revises Guidance 65 Collaborators Publish 65 Options Activity 65 Provides Comprehensive 65 Spins Off 65 Successfully Completes Acquisition 65 Announces Consummation 65 Enters Into Exclusive 65 Announce Availability 65 Reduces Debt 65 Shareholders Approve Sale 65 Shares Plummet 65 Stock Soars 65 Trend Continues Down 65 widens Quick Facts 65 Makes Significant 65 Fortifies 65 Reaffirms Commitment 65 Declares Quarterly Distribution 65 Receives Notice Regarding 65 Engages CHF Investor Relations 65 Schedules Third Quarter 65 Reclassifies 65 Clinical Trial Evaluating 65 Issues Clarification 65 Drilling Confirms 65 Reschedules 65 Introduces Enhanced 65 Engages Investor Relations 65 Previously Treated 65 StockGuru announces 65 ISS Recommends 65 Forms Strategic 65 Bearish Technical 65 Announces Restatement 65 Stock Upgraded 65 Bullish Engulfing Pattern 65 Bullish Speculation 65 Enters Strategic 65 www.shamrockstocks.com names 65 Announce Third Quarter 65 Puts Purchased 65 Files Investigational 65 Retains 65 Signs Joint Venture 65 From Cont 65 Finalizes Sale 64 Confirms Efficacy 64 Calls Purchased 64 Initiate Phase 64 Completes Recapitalization 64 Signs Binding Letter 64 Disappoints 64 Q1 Adj 64 Awarded Contract 64 Patients Treated 64 Substantially Increases 64 4Q Loss Widens 64 Temporarily Suspends 64 Stockholders Approve Acquisition 64 Receives CE Marking 64 Files Restated 64 Revolutionizes 64 Exercises Warrants 64 Enters Exclusive 64 otcstockexchange.com 64 Bolsters 64 STOCK MARKETING INC PRESENTS 64 Expands Scope 64 Bullish Technical Alert 64 Bullish Average Crossover 64 CFO Resigns 64 Combination REOLYSIN R 64 Enters Into Licensing Agreement 64 Achieves Highest 64 Continues Aggressive 64 Enters Negotiations 64 Loss Narrows 64 Receives Approvals 64 DALLAS TEXAS StockGuru announces 64 Signs Exclusive 64 Announces Delisting 64 Announces Webcast 64 Declares Quarterly Dividends 64 Investigational Treatment 64 Daytradersdigest.com 64 Mails Offer 64 Widens Quick Facts 64 Moves Towards 64 Reinforces 64 Phase 2b Study 64 Files Patent 64 #.#/Share [002] 64 Pivotal Study 64 Extends Collaboration 64 FDA Approvals 64 Acquire Remaining 64 Recommends Approval 64 Vaccine Adjuvant 64 Closes Over Allotment 64 Sets Record Date 64 Inks Deal With 64 Million Financing 64 Commercializes 64 Anounces 64 Completes Transition 64 Q1 Profit Surges 64 Increases Quarterly Cash Dividend 64 Resigns Quick Facts 64 Technicals Showing Bullish 64 NYMH Announces 64 Announces Profitable 64 Q2 Profit Surges 64 Regains NASDAQ 64 Protease Inhibitor 64 Introduces Innovative 64 Shareholders Approve Arrangement 64 Boosts Stake 64 Continues Expansion 64 Have Been Added 64 pralatrexate injection folate analogue 64 Finalises 64 Revises Fourth Quarter 64 Moves Ahead 64 Renews Agreement 64 Bearish Dark 64 Increases Quick Facts 64 Corp. Joins OTCQX 64 Completes Non Brokered 64 Taro Receives 64 Report Examines 64 Expands 64 Study Validates 64 Declares Second Quarter 64 Publishes 64 Broadens Its 64 Wins Prestigious 64 Forges Ahead 64 Announces Tender Offer 64 Files Annual Report 64 Obtains Exclusive License 64 CONFERENCE CALLS SOURCE 64 Posts Lower 64 Introduces Breakthrough 64 Reach Agreement 64 Miraculins Announces 64 Expands Distribution 64 Patent Issued 64 Commences Initial 64 Posts Large 64 Other OTC USOG 64 Improves Outcomes 64 Expand Relationship 64 Cloud Cover Pattern 64 Extends Contract 64 Declares Cash Dividend 64 Bearish Speculation 64 Debuts 64 Announces Fourth Quarter 64 Unveils Next Generation 64 Completes Redemption 64 Awarded Patents 64 Receives Notice From 64 Post Earnings Checkup 64 Appoints Experienced 64 Study Identifies 64 Introduces 64 TSX TVI OTCQX 64 Unveils Expanded 64 Announce Exclusive 64 Preliminary Fourth Quarter 64 Earnings Postmortem 64 Sweetens Bid 64 Seek Shareholder Approval 64 :/ finance.yahoo.com q 64 Report Indicates 64 Reactivates 64 FY# Loss Narrows 64 Interesting Options Volume 64 Phase 1b Clinical Trial 64 Files Voluntary 64 Reaffirms 64 Receives Authorization 64 Reorganizes 64 Subsidiaries Selected Financial 64 Generates Record 64 Loss Widens 64 Inc Therapeutic Competitors 64 Sign Definitive Merger 64 Drilling Resumes 64 Announce Partnership 64 Withdraws 64 Announce Strategic 64 Redeems 64 Sees Strong 64 TheWallStreetLeader.com Profiles 64 Gets Boost 64 Earns 64 Signs Contract 64 Exceeds Expectations 64 Announces Ticker Symbol 64 Trend Continues Lower 64 Raises Stake 64 Posts Profit 64 Receive Milestone Payment 64 Posts Narrower Loss 64 Reveals 64 Sets Record 64 1st Quarter Results 64 Reaches Milestone 64 PROFILE CO 64 Delivers Strong 64 Recieves 63 Increases Quarterly Dividend 63 Concludes Successful 63 Alert Technicals Showing Bearish 63 Commences Drilling Operations 63 Chronic Hepatitis C 63 Joins 63 Posts Wider 63 Trend Continues Up 63 Revenues Increase 63 Strengthens Leadership 63 Retains Leading 63 Announces Definitive Agreements 63 Posts 4Q 63 Patients Treated With 63 Announces Recapitalization 63 Continues Momentum 63 Host Fourth Quarter 63 Initiate Clinical Trial 63 Rebrands 63 Warrants Exercised 63 Declares Fourth Quarter 63 Holds Annual Meeting 63 Guides Above 63 Closes Oversubscribed 63 Maintains Buy Rating 63 Profitable Quarter 63 Strengthens Position 63 NDA Submission 63 Provide Comprehensive 63 Redhotpennystock.com Alert 63 Beats Analyst 63 Lowers Guidance 63 Subsidiary Awarded 63 Announces Sponsorship 63 Accelerates 63 Rejects Unsolicited 63 Repositions 63 Declares Regular Quarterly 63 Eaton Vance Closed End 63 Release Second Quarter 63 Above Estimates 63 Launches 63 Announces Mailing 63 Unveils Innovative 63 Settle Patent Dispute 63 News Unternehmensnachrichten 63 Closes Private Placements 63 Expert Joins 63 Nominates 63 Amend Merger Agreement 63 FDA Panel Recommends 63 Expands Presence 63 Million Private Placement 63 Prolongs Survival 63 Patients Suffering 63 Elects 63 Extends Relationship 63 Technicals Showing Bearish 63 Effectively Treats 63 Announces Favorable Ruling 63 Alert Technicals Showing Bullish 63 Mln Common 63 Sees Higher 63 Moving Average Crossover Alert 63 Announces Affiliation 63 Awarded Multi 63 Delivers Solid 63 Announces Stock Buyback 63 Reschedules Fourth Quarter 63 Clears Path 63 JAK2 Inhibitor 63 Forecast Quick Facts 63 Proves Successful 63 Inks Agreement 63 Positions Itself 63 Receives Recognition 63 Oceaneering Announces 63 Schedules Fourth Quarter 63 Host Second Quarter 63 Record Fourth Quarter 63 Analysts Begin Coverage 63 Snaps Up 63 Enters Into Collaboration 63 Completes Asset 63 Raises Guidance 63 Thewallstreetleader.com Profiles 63 Terminates Merger Agreement 63 Increases Risk 63 Pivotal Phase 63 Anticipates 63 Terminate Merger Agreement 63 Enters Final 63 Mylan Receives Approval 63 II Clinical Trial 63 Provides Detailed 63 Has Entered 63 Launches Unique 63 Q4 Profit Plunges 63 Moves Into 63 Congratulates 63 Successfully Launches 63 Declares Quarterly Cash Dividend 63 Up Sharply 63 Other OTC MNDP 63 Gold Intersects 63 Milestone Payment 63 Launches Generic Version 63 Receives Stockholder Approval 63 Has Returned 63 Webcast Presentation 63 Realigns 63 Drug Shows Promise 63 Statement Regarding 63 Pending Acquisition 63 Expands Portfolio 63 Announce Joint Venture 63 Obtains Patent 63 Wins Contract 63 Underwriters Exercise 63 Announces Definitive Merger 63 Earnings Decline 63 Web Site www.kinbauri 63 Osteoporosis Drug 63 Equity Funds Declare 63 Narrows Guidance 63 Medoro Resources Announces 63 Updates Outlooks 63 Teva Provides Update 63 Enters Into Negotiations 63 Subsidiary Completes 63 Bearish Harami Pattern 63 CONTINUES LOWER 63 OTC BB ELRA 63 Planned Acquisition 63 Rises Quick Facts 63 Receives Funding 63 Affirms Commitment 63 Acquires Remaining Interest 63 Sees Significant 63 Achieves Profitability 63 Private Placement Financing 63 Coverage Initiated 63 Pharmaceuticals Initiates 63 Projected Release Date 63 Announce Formation 63 Investigational Oral 63 Equity Preview 63 Acquires Majority Stake 63 Begins Shipping 63 CONFERENCE CALLS EARNINGS SOURCE 63 Breaks Through 63 Extends Term 63 Strikes Deal 63 Patent Infringement Lawsuit Against 63 Restructures Debt 63 Sells Stake 63 Further Validates 63 Acquire Majority 63 Extends Reach 63 Release Third Quarter 63 Downgrade Alert Watch 63 Gout Drug 63 Stock Downgraded 63 Urges Shareholders 63 Has Risen 63 Migraine Drug 63 REPLACING 63 Launches Website 63 Inks MOU 63 Posts Solid 63 Reacquire 63 Initiates Voluntary Recall 63 Shares Plunge 63 Receives Accreditation 63 Reaches Settlement 63 Increases Cash Dividend 63 Acquires Majority 63 Pave Way 63 Hold Fourth Quarter 63 DayTradersDigest.com Profiles 63 Announces Quarterly Dividend 62 Is Well Tolerated 62 Beefs Up 62 www.bharatbook.com 62 Announce Fourth Quarter 62 Signs Merger Agreement 62 Subsidiary Purchases 62 Demonstrates Statistically Significant 62 Announce Filing 62 Bearish MACD 62 Largest Shareholder 62 Settles Dispute 62 Guides Inline 62 Outshines 62 Magazine Recognizes 62 Assumes Role 62 View Quick Facts 62 Activity Alert 62 Secures Contract